Canaccord lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $4 from $6 and keeps a Buy rating on the shares. The firm two key updates from the company; the lifting of the clinical hold on the MyPEAK-1 trial of TN-201 by the FDA and the first look at interim data from the RIDGE-1 Ph1B clinical trial of TN-401 for PKP2-associated ARVC.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Promising Initial Data and Safety Profile Justify Buy Rating for Tenaya Therapeutics’ TN-401
- Tenaya Therapeutics Announces Public Offering Pricing
- Promising Clinical Developments and FDA Approval Boost Tenaya Therapeutics’ Buy Rating
- Tenaya Therapeutics price target lowered to $3 from $5 at H.C. Wainwright
- 3 ‘Strong Buy’ Stocks to Buy Today, 12/12/2025, According to Top Analysts